MedWatch

Audientes CEO: We have the perfect product for the future OTC channel

Hearing aid firm Audientes is seeing dollar signs on the future OTC market for hearing aids in the US. For this reason, the firm is now doing everything in its power to get low-cost hearing aids approved by the US Food and Drug Administration.

Audientes CEO Steen Thygesen | Photo: Audientes / PR

The US is undoubtably the largest single market in the hearing industry, and when the new regulation on over-the-counter sales of hearing aids is implemented, probably in a few years' time, sales will blossom for the companies that are selling low-cost hearing devices.

One of these is Danish company Audientes, which entered the Nasdaq First North stock exchange in September last year and is now betting on getting permission from the US health authorities to sell and market its low-cost hearing aid to US residents.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs